Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

64 results about "P2x7 receptor" patented technology

P2X7 receptors are extracellular ATP-gated ion channels that play broad physiological and pathological roles in animals (Sluyter, 2017). Activation of P2X7 receptors lead to the opening of membrane channels permeable for small cations like Na + and Ca 2+ as well as fluorescent dyes such as YO-PRO-1 (Alves et al., 2014).

Antibodies against non functional p2x7 receptor

A recombinant or synthetic antibody or fragment thereof, said antibody or fragment thereof including three complementarity determining regions (CDR1L or H, CDR2L or H and CDR3L or H) for forming an antigen binding site that is capable of binding to a non functional P2X7 receptor but not capable of binding to a functional P2X7 receptor.
Owner:BIOSCEPTRE INT

Methods and Compositions to Inhibit P2x7 Receptor Expression

Methods and compositions for the downregulation of P2X7 receptor expression or activity are disclosed. Preferred compositions comprise siNA. The methods and compositions are useful in the treatment of diseases characterised by increased 112X7 receptor activity, such as neuronal degeneration, Alzheimer's disease, inflammatory diseases, and some cancers.
Owner:SYLENTIS

Combination Therapy

ActiveUS20150004179A1Minimizing progressionLonger and greater exposure to cell surface P2XSnake antigen ingredientsCancer antigen ingredientsBody fluidCombination therapy
Owner:BIOSCEPTRE PTY LTD

Cannabinergic lipid ligands

One aspect of this disclosure relates generally to lipid compounds that exert diverse effects in the endocannabinoid system, such as regulating CB1 and CB2 receptor or moderating other bio-macromolecules within the endocannabinoid system. Some of the compounds showed improved receptor binding affinity, and / or improved receptor subtype selectivity, and improved bio-stability. Some of the compounds exhibit activities to regulate the enzymes that moderate the bio-disposal of endogenous cannabinoids, such as the fatty acid amide hydrolase (FAAH). Some of the compounds exhibit activities to inhibit the anandamide transporter. Other aspects of the invention are pharmaceutical preparations employing these ligands and methods of administering therapeutically effective amounts of the preparations to provide a physiological effect.
Owner:UNIV OF CONNECTICUT

P2x7 receptor agonist for use in preventing or treating kidney injury

The present invention relates to the treatment or prevention of kidney injury and in particular acute kidney injury, such as acute kidney injury associated with cirrhosis. The invention relates to the treatment or prevention of such injury by administration of an agonist of the P2X7 receptor.
Owner:UCL BUSINESS PLC

P2X7 receptor imaging agent and preparation method thereof

The invention discloses a F-18 tagged P2X7 receptor imaging agent which is a compound 18F-{(2-chloro-3-trifluorophenyl)(1-(pyrimidin-2-yl)-6,7-dihydro-1H-[1,2,3]triazolo[4,5-c]pyridin-5(4H)-yl)methanone shown as formula I. The P2X7 receptor imaging agent is suitable for identifying and diagnosing pulmonary inflammation and tumors.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV

Methods and compositions to inhibit p2x7 receptor expression

Methods and compositions for the downregulation of P2X7 receptor expression or activity are disclosed. Preferred compositions comprise siNA. The methods and compositions are useful in the treatment of diseases characterised by increased P2X7 receptor activity, such as neuronal degeneration, Alzheimer's disease, inflammatory diseases, and some cancers.
Owner:SYLENTIS

Application of P2X7 receptor inhibitor

InactiveCN105078948AOrganic active ingredientsNervous disorderActivated microglial cellInjury brain
The invention discloses application of a P2X7 receptor inhibitor in the preparation of drugs for treating radiation brain injuries. Through experimental deep research on pathogenesis of radiation brain injuries and effect of a P2X7 receptor upon occurrence and development of the radiation brain injuries, discovered is that radioactive rays activating microglial cells by the P2X7 receptor cause following inflammatory response, the P2X7 receptor specific inhibitor BBG is effective in inhibiting this response, and nerve cells are thereby protected; the inhibitor is applicable to the treatment of radiation brain injuries.
Owner:SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV

Therapies for Disorders of the Cornea and Conjunctiva

Unexpectedly, disorders of the cornea and conjunctiva are found to be caused or to be exacerbated, at least in part, by extracellular ATP and P2X7 receptor activation. Therapeutic compositions for topical administration to the eye for the treatment of disorders of the cornea and conjunctiva include an entity that inhibits P2X7 receptor function, reduces the effective concentration of extracellular ATP, or both.
Owner:KALEKO MICHAEL

Method For Treatment Of Macular Degeneration By Modulating P2Y12 or P2X7 Receptors

Provided is a method of treating or preventing age-related macular degeneration (AMD) in a patient subject to, or symptomatic of the disease, wherein the method comprises restoring normal lysosomal pH (pHL), or acidifying an abnormally elevated pHL, thus decreasing or preventing a damaging accumulation of lipofuscin or waste products in the retinal pigment epithelium (RPE) cells of the eye of the patient. Further, this method is achieved by modulating the action of the P2X7 and / or P2Y12 receptors of the RPE cells, specifically decreasing the acidity (pHL) of the RPE lysosomes by administering selected receptor antagonists affecting the action of the P2X7 and / or P2Y12 receptors of the RPE. Methods for selecting and quantifying the effectiveness of drugs to restore pHL and determine outer segment clearance rates is also provided using a high through-put screening protocol.
Owner:MITCHELL CLAIRE +1

Tyrosyl derivatives and their use as P2X7 receptor modulators

The present invention relates to compounds of the formulawherein R1 and R2 are independently hydrogen, C1–C4 alkyl, C1–C4 substituted alkyl, C1–C4 alkoxy, C1–C4 substituted alkoxy, C1–C4 acyl, halogen, cyano, nitro, amino, alkylamino, or dialkylamino;R3, R4, R5, R6, R7, and R8 are independently CH or nitrogen;R9 is hydrogen or methyl;R10 is C═O or (CH2)n;where n is 0, 1, 2, 3, or 4;R11 and R12 are independently nitrogen or CH; X1 and X2 are independently hydrogen, deuterium, tritium or halogen; and X3 is N; and their pharmaceutically acceptable salts; compositions thereof. Methods of preparing the compounds are also described. The compounds are useful in the treatment of diseases in mammals that are mediated by the action of the P2X7 receptor.
Owner:BARALDI PIER GIOVANNI +1

Nanosuspension of P2X7 receptor antagonist employing isoquinoline as basic skeleton and preparation method of nanosuspension

The invention discloses a nanosuspension of a P2X7 receptor antagonist employing isoquinoline as a basic skeleton and a preparation method of the nanosuspension, and belongs to the field of medicinal preparations. As a novel P2X7 receptor antagonist, the major indications are labour pains, inflammation, respiratory tract and airway diseases and obstacles and the like. The medicine is extremely difficult to dissolve in water, so that the clinical application is limited. The nanosuspension is prepared by an antisolvent precipitation method combined with a high pressure homogenization method; and the prescription and technology are optimized employing the particle sizes and a polydispersity index as indexes. The result shows that the particle sizes of the medicines in the prepared nanosuspension are 50-500nm; the nanosuspension is round in shape and uniform in distribution; the particle sizes are reduced; increase of the medicine solubility is facilitated; and the in vitro dissolubility is improved.
Owner:CHINA PHARM UNIV

Cannabinergic Lipid Ligands

One aspect of this disclosure relates generally to lipid compounds that exert diverse effects in the endocannabinoid system, such as regulating CB1 and CB2 receptor or moderating other bio-macromolecules within the endocannabinoid system. Some of the compounds showed improved receptor binding affinity, and / or improved receptor subtype selectivity, and improved bio-stability. Some of the compounds exhibit activities to regulate the enzymes that moderate the bio-disposal of endogenous cannabinoids, such as the fatty acid amide hydrolase (FAAH). Some of the compounds exhibit activities to inhibit the anandamide transporter. Other aspects of the invention are pharmaceutical preparations employing these ligands and methods of administering therapeutically effective amounts of the preparations to provide a physiological effect.
Owner:UNIV OF CONNECTICUT

Modified pyr/pyl receptors activated by orthogonal ligands

The present invention provides polynucleotides encoding mutated PYR / PYL receptor polypeptides that are agonized by chemicals, such as bromoxynil, chloroxynil, ioxynil, coumatetralyl, dichlobenil, fenhexamid, benoxacor, and BTH, that do not agonize wild-type PYR / PYL receptor polypeptides, and expression cassettes and plants comprising the polynucleotides. Particular embodiments of the invention provide polynucleotides encoding mutated PYR / PYL receptor polypeptides having a mutation in the ligand-binding pocket of the PYR / PYL receptor polypeptide.
Owner:RGT UNIV OF CALIFORNIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products